Skip to main content
. 2019 Feb 28;43(5):590–606. doi: 10.4093/dmj.2018.0134

Fig. 1. Flow diagram of study subjects. SGLT2i, sodium-glucose cotransporter-2 inhibitor; HbA1c, glycosylated hemoglobin; OAD, oral anti-diabetic drug; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase 4 inhibitor; TZD, thiazolidinedione.

Fig. 1